Avinger (NASDAQ:AVGR) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Avinger (NASDAQ:AVGR) in a research report report published on Tuesday morning. The brokerage issued a hold rating on the medical device company’s stock.

Avinger Stock Up 2.1 %

NASDAQ AVGR opened at $0.97 on Tuesday. Avinger has a 52 week low of $0.90 and a 52 week high of $6.55. The firm has a market capitalization of $1.65 million, a price-to-earnings ratio of -0.05 and a beta of 1.17. The company has a fifty day moving average of $1.18 and a two-hundred day moving average of $2.20.

Avinger (NASDAQ:AVGR) last issued its quarterly earnings results on Thursday, August 8th. The medical device company reported ($2.82) EPS for the quarter, missing the consensus estimate of ($0.43) by ($2.39). The company had revenue of $1.85 million for the quarter, compared to the consensus estimate of $2.55 million. Equities research analysts anticipate that Avinger will post -4.69 EPS for the current year.

Institutional Investors Weigh In On Avinger

A hedge fund recently bought a new stake in Avinger stock. Armistice Capital LLC bought a new position in Avinger, Inc. (NASDAQ:AVGR) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 43,747 shares of the medical device company’s stock, valued at approximately $81,000. Armistice Capital LLC owned 2.57% of Avinger as of its most recent SEC filing. 18.30% of the stock is currently owned by institutional investors.

About Avinger

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.